Eli Lilly shares rose 3.6% on Tuesday after completing a previously announced deal with AlzeCure Pharma for its preclinical Alzheimer’s drug candidate ACD680 — finalizing the initial transaction with a $10 million upfront payment — and entering a separate collaboration with OmniAb for an ion channel program, adding yet another chapter to what is becoming one of the most consequential pipeline stories in modern pharmaceutical history. The move extended gains from a record-setting second quarter, and it raised a question investors have been wrestling with since August 5: after all of this, is Eli Lilly (NYSE: LLY) still a buy?
The honest answer requires separating what Lilly has already delivered — a Q2 2026 earnings beat so large it forced Wall Street to revise its models upward — from what Lilly is still building: a next-generation weight-loss drug whose legal exclusivity structure is more durable than almost anything else in the company’s pipeline, and which the current stock price may not fully reflect
The numbers from Lilly’s second quarter, reported August 5, were not good — they were structurally exceptional. Revenue rose 48% year over year to $22.97 billion, beating analyst consensus by more than $2.5 billion — an 11% top-line surprise in a quarter when investors already expected significant growth. Non-GAAP earnings per share reached $8.38, up 33% from the prior year, exceeding analyst estimates by roughly 39%
Record Quarter That Reset Expectations
Mounjaro, the tirzepatide drug Lilly markets for type 2 diabetes, delivered $9.94 billion in quarterly revenue — a 91% year-over-year increase — as the drug’s addition to China’s National Reimbursement Drug List opened a new high-volume market. The SEC 8-K filing confirms Zepbound, tirzepatide’s obesity-approved twin, added another $4.93 billion, up 46%. Together, the two tirzepatide products generated $14.87 billion in a single quarter and $27.69 billion in the first half of 2026 — a combined revenue pace that no drug franchise in pharmaceutical history has previously achieved at this stage.
Management raised full-year 2026 revenue guidance for the second time this year, now expecting $85 billion to $87 billion, up from a prior range of $82 billion to $85 billion. LLY stock gained approximately 6.3% during the August 5 trading session, recovering from a five-day selloff that had taken the stock down roughly 8.6% heading into earnings
Foundayo’s Oral Advantage — and Its Limit
Lilly’s second-quarter results introduced investors to an early but meaningful new growth signal: Foundayo (orforglipron), the company’s once-daily oral GLP-1 pill, generated $98 million in sales in its first full quarter on the US market. The prescriber base reportedly grew from roughly 8,000 to 36,000 physicians during the quarter, suggesting a ramp trajectory comparable to what Zepbound saw in its own early quarters
What makes Foundayo structurally significant — and what the Q2 sales figure alone doesn’t convey — is the chemistry underlying its oral viability. Unlike tirzepatide, semaglutide (Wegovy, Ozempic), and the investigational retatrutide, all of which are peptide-based molecules that digestive enzymes break down if swallowed, orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist. That chemical distinction means it resists degradation in the gastrointestinal tract, reaches the bloodstream intact after swallowing, and can be taken at any time of day without food or water restrictions — something no injectable or oral semaglutide (which requires fasting and a mandatory 30-minute delay before eating) can claim.
The practical expansion argument is real. Studies consistently show that a meaningful portion of patients who might benefit from GLP-1 therapy decline to start because they are unwilling to self-inject. An oral alternative removes that barrier entirely. Foundayo’s self-pay price of $149 per month in the US also positions it well below injectable list prices, and eligible Medicare Part D beneficiaries gained access through the Medicare GLP-1 Bridge Program beginning July 1, 2026, at a $50-per-month cap alongside Zepbound and Wegovy.
On August 10, the UK’s Medicines and Healthcare products Regulatory Agency approved Foundayo in Europe — the first regulatory clearance for orforglipron on the continent, making the UK the first country to approve the drug. The approval covers adults with a body mass index of 30 or above, and adults with a BMI between 27 and 30 with at least one weight-related health condition, as well as patients with insufficiently controlled type 2 diabetes. Lilly stock rose more than 3% on the day of the UK announcement. A UK National Institute for Health and Care Excellence reimbursement decision — which will determine whether the National Health Service covers Foundayo for routine prescribing — is expected on November 18, 2026.
The limit that matters for investors: Foundayo has not completed a cardiovascular outcomes trial. Unlike oral semaglutide, which demonstrated cardiovascular benefits in SOUL trial, orforglipron lacks that evidence base. For high-risk patients — the precise population most likely to be prescribed a GLP-1 drug by a cardiologist — clinicians must weigh Foundayo’s convenience advantages against the absence of the outcomes data that makes prescribing a straightforward decision. That data gap will constrain Foundayo’s penetration in high-risk patient segments until a cardiovascular outcomes trial is completed, a process that typically takes four to five years.
Drug Wall Street Is Sleeping On
If Foundayo is the story investors can already model, retatrutide is the one they may be underweighting — particularly in one dimension
The Phase 3 clinical case for retatrutide is settled. TRIUMPH-1, announced May 22, 2026, showed that participants on the highest dose of retatrutide (12 mg weekly) lost an average of 28.3% of their body weight — approximately 70 pounds — over 80 weeks, in a trial of 2,339 adults. That figure represents the highest weight-loss result ever recorded in a large pharmacological Phase 3 trial: above semaglutide’s 14.9%, above tirzepatide’s 22.5%, and within the range historically associated only with bariatric surgery.
Two additional Phase 3 trials reported July 23 — TRIUMPH-2 and TRIUMPH-3, testing retatrutide in adults with obesity and type 2 diabetes and in adults with obesity and cardiovascular disease, respectively — produced weight losses of 20.8% and 22.6% at 80 weeks alongside improvements in A1C, blood pressure, and triglycerides
Why Retatrutide Works Differently
The mechanism explains the magnitude. Retatrutide is a triple hormone receptor agonist — it simultaneously activates three metabolic hormone receptors that no currently approved drug touches at once. GLP-1 receptor activation suppresses appetite and slows gastric emptying; GIP (glucose-dependent insulinotropic polypeptide) receptor activation amplifies insulin secretion and enhances fat metabolism in adipose tissue — the combination that makes tirzepatide more effective than semaglutide. Retatrutide adds a third receptor: glucagon, which activates thermogenesis in brown adipose tissue and increases hepatic fat oxidation in ways that neither tirzepatide nor semaglutide can achieve. That third mechanism is the architectural source of the superior weight-loss outcomes.
Lilly confirmed in July that the clinical data package is now complete to support global regulatory submissions for obesity, obstructive sleep apnea, and knee osteoarthritis, and plans to submit a BLA to FDA in the first quarter of 2027
Here is the piece most financial coverage has not explicitly quantified: because retatrutide is a peptide, it travels the Biologics License Application regulatory pathway rather than the standard small-molecule New Drug Application pathway. That matters structurally for investors. Under the Biologics Price Competition and Innovation Act, an approved biological product receives 12 years exclusivity before a biosimilar can enter — compared to 5 years for a small-molecule drug under the Hatch-Waxman Act. If retatrutide receives FDA approval in late 2027 or early 2028, as expected under the standard 10-to-12-month review timeline, that 12-year exclusivity window means the earliest a biosimilar could legally compete would be approximately 2039. No other drug in Lilly’s current obesity portfolio carries that structural protection through the late 2030s.
Beyond GLP-1: Diversification Is Already Happening
The cardiometabolic franchise may be what drives Lilly’s market cap, but the diversification argument has become concrete rather than aspirational. Key Product revenues outside cardiometabolic health — spanning immunology, oncology, and neuroscience — grew 121% in the second quarter compared with the same period last year. That figure includes Kisunla for early Alzheimer’s disease, Inluriyo for metastatic breast cancer, Omvoh for inflammatory bowel disease, Jaypirca for chronic lymphocytic leukemia, and Ebglyss for atopic dermatitis.
Tuesday’s deal news extended that diversification forward. Lilly completed the acquisition of global rights to AlzeCure Pharma’s ACD680 — a preclinical Alzheimer’s drug candidate — for a $10 million upfront payment, with total potential value exceeding $1 billion through future development and commercial milestone payments plus mid-single-digit royalties. ACD680 is intended to sit upstream of Kisunla in Lilly’s Alzheimer’s disease pipeline, addressing patients at an earlier disease stage — a classic portfolio-building move that costs relatively little upfront while potentially protecting long-term franchise position. In a separate announcement, Lilly entered a global collaboration with OmniAb for an ion channel program, offering OmniAb an upfront payment and up to $370 million in milestones plus tiered royalties.
These low-upfront, milestone-structured deals have become the company’s standard approach to early-pipeline building. In 2026 alone, Lilly completed acquisitions of Orna Therapeutics (circular RNA, up to $2.4 billion), Kelonia Therapeutics (lentiviral in vivo CAR-T, up to $7 billion), Ajax Therapeutics, Centessa Pharmaceuticals, and three additional companies to build an infectious disease portfolio, as well as an agreement to acquire AtaiBeckley for treatment-resistant depression. The company also committed an additional $4.5 billion to expand Indiana manufacturing sites, addressing one of the most frequently cited constraints on Lilly’s growth: its ability to manufacture enough product to meet surging demand.
Competition Heats Up in the Oral Race
Lilly’s early lead in oral GLP-1 drugs is real but contested. Novo Nordisk gained regulatory approval for an oral version of its obesity drug Wegovy in December 2025, launched in January 2026, and reported approximately $500 million in Q2 2026 sales from the oral formulation, with total prescriptions reaching roughly 2.9 million. That $500 million figure from an established brand with a head start illustrates both the market’s appetite for oral options and the catch-up dynamic Foundayo faces despite its dosing flexibility advantage. Novo Nordisk has also experienced significant pipeline setbacks in 2026 — including the failure of its cardiovascular drug ziltivekimab in the Phase 3 ZEUS trial and the discontinuation of obesity candidate monlunabant over neuropsychiatric safety concerns — leaving it more dependent than expected on its existing approved products.
Earlier-stage competitors are advancing but remain years away from commercial relevance. Viking Therapeutics’ dual GIP/GLP-1 agonist VK2735 is expected to enter Phase 3 development for obesity in the fourth quarter of 2026. Structure Therapeutics recently initiated its Phase 3 ACCOMPLISH program for aleniglipron. Neither represents near-term competitive pressure on Lilly’s core franchise
Valuation: Premium That May Be Understating the Moat
At current levels near $1,225 per share, LLY trades at approximately 28 times forward earnings. That figure sits above the pharma industry average of roughly 18 times but below Lilly’s own five-year mean of approximately 34.6 times — a historical context suggesting the stock is not at peak valuation relative to its own track record, even after the 2026 run-up
The standard comparison — Novo Nordisk’s lower forward multiple against Lilly’s premium — understates the asymmetry in pipeline position. Novo faces confirmed pipeline setbacks and a more concentrated product portfolio. Lilly enters the second half of 2026 with a confirmed retatrutide BLA timeline, a global oral pill expansion in progress, and a non-GLP-1 product portfolio growing at triple-digit rates. The retatrutide exclusivity window — biological protection through approximately 2039 under BLA approval — represents an economic moat that standard earnings multiples don’t directly capture.
The risks are real. Drug pricing in the US continues to compress: prices across most of Lilly’s products fell in first-half 2026, with price erosion expected to reduce top-line growth by a mid-teens percentage for the full year. Late-lifecycle products including Trulicity, Taltz, and Verzenio face flat-to-declining revenues. Second-half comparisons will be tougher, as the rebate and discount estimate adjustments that benefited first-half results are not expected to recur, and seasonal slowdowns in European markets add additional noise. The $2.78 billion in in-process research and development charges incurred during Q2 — primarily from Orna Therapeutics and Ajax deals — elevated the effective tax rate to 23.3%, compared with 16.5% in Q2 2025. On the shareholder activity side, insider transactions have skewed toward net selling in recent months — a data point that doesn’t reverse the investment case but is worth registering. And the 4,400-plus lawsuits filed in multidistrict litigation against Lilly and Novo Nordisk, alleging failure to warn about gastroparesis and vision loss associated with existing tirzepatide and semaglutide products, represent an unresolved legal liability for which no settlement estimate is publicly established.
What to Watch Before Deciding
For investors evaluating LLY at these levels, the decisions that will move the stock most are predictable: prescription demand in Foundayo’s international markets (the UK private launch is expected in late August 2026), the NICE reimbursement ruling on November 18, the Q3 2026 earnings call expected late October, and the timing and any Priority Review designation for the retatrutide BLA filing in Q1 2027. A Priority Review designation from the FDA — which the agency grants when a drug addresses a serious condition and may provide a meaningful therapeutic advance — would compress the review window from 10 to 12 months to roughly six to eight months, potentially accelerating FDA approval into late 2027 rather than early 2028.
The Q2 2026 results established what Lilly is. The retatrutide BLA timeline and its accompanying biological exclusivity will determine what Lilly is worth in 2028 and beyond. Investors who buy today are not paying a steep premium by historical standards — but they are accepting 12 to 18 months of pipeline execution risk between now and the moment retatrutide begins generating revenue. Tuesday’s Alzheimer’s acquisition and OmniAb collaboration are not the story; they are evidence that management is building the next chapter while the current one — retatrutide’s regulatory path — plays out. Whether that risk/reward balance is acceptable depends on how investors weight a structural exclusivity moat against a filing timeline that won’t resolve until 2027.
Read more:Eli Lilly Formalizes Retatrutide Access With Criteria Most Patients Cannot Meet
Frequently Asked Questions
Is Eli Lilly stock a buy right now?
The company’s fundamentals are exceptional — 48% revenue growth in Q2 2026, guidance raised to $85 to $87 billion for the full year, and a retatrutide pipeline that carries 12-year biological exclusivity if approved. Lilly’s current forward P/E of approximately 28 times is below its own five-year historical mean, which some analysts read as room for expansion. The risk is execution on the retatrutide BLA timeline: a filing is planned for Q1 2027, with FDA approval not expected before late 2027 at the earliest. Investors willing to accept 12 to 18 months of regulatory uncertainty before the next major revenue catalyst materializes are buying at a historically below-mean valuation. Those who need near-term catalysts may prefer to wait for the NICE reimbursement decision on November 18 or the Q3 earnings report in late October, both of which could move the stock meaningfully in either direction. As with any investment decision, consult a qualified financial adviser before acting.
How does retatrutide work differently from Zepbound, and why does it matter for investors?
Zepbound (tirzepatide) activates two hormone receptors — GLP-1 and GIP — and produced roughly 22.5% average weight loss in Phase 3 trials. Retatrutide adds a third receptor: glucagon, which activates thermogenesis in brown adipose tissue and increases fat burning in the liver via pathways tirzepatide cannot access. That third mechanism is the reason retatrutide achieved 28.3% weight loss in its pivotal Phase 3 trial — the highest ever recorded in a large pharmacological obesity trial, previously achievable only through bariatric surgery. For investors, the mechanism matters beyond efficacy: retatrutide is a biological peptide subject to the Biologics License Application regulatory pathway, which grants 12 years of market exclusivity after approval under federal law. That protection pushes biosimilar competition to approximately 2039, a structural advantage not present for small-molecule GLP-1 drugs.
What is Foundayo, and how is it different from other GLP-1 drugs?
Foundayo (orforglipron) is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist approved by the FDA in April 2026 and by the UK’s MHRA on August 10, 2026. Unlike all other GLP-1 obesity drugs — which are peptide molecules that digestive enzymes break down and that must be injected — orforglipron is a small-molecule, non-peptide compound that survives the digestive process intact. This allows it to be taken by mouth, at any time of day, with no food or water restrictions. Its US self-pay price is $149 per month, and eligible Medicare Part D beneficiaries can access it through the GLP-1 Bridge Program for $50 per month. The trade-off: unlike oral semaglutide, which demonstrated cardiovascular mortality benefits in the SOUL trial, orforglipron has not yet completed a cardiovascular outcomes trial — a data gap that will limit prescribing in high-risk patient populations until that evidence is available.
When will retatrutide be available at a regular pharmacy?
Eli Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027. Under the standard FDA review timeline of 10 to 12 months, approval would follow in late 2027 to early 2028 at the earliest, with commercial launch typically arriving several months after that. A Priority Review designation could accelerate approval modestly. The Medicare GLP-1 Bridge Program, which currently covers Zepbound, Wegovy, and Foundayo, covers only FDA-approved drugs — retatrutide will not be accessible through that program until after approval is granted. For more detail on Lilly’s access criteria for retatrutide ahead of approval, see our prior coverage at TechTimes.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission
Tags:Eli Lilly
